Análisis de la acción Seaport Therapeutics Inc (SPTX)SPTXSeaport Therapeutics Inc

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD. It operates in the Healthcare sector.

Seaport Therapeutics, Inc. is a good buy right now due to its strong cash position of $427.3 million, which supports operations through 2029, and the positive sentiment from analysts, with a target price of $32 from Jones and $50 from H.C. Wainwright. The main risk is the recent widening net loss of $62.6 million in Q2 2026, which could affect investor confidence.